Partnering Terms and Agreements in Infectives Segment Analysed by CurrentPartnering
20 Jul 2012 • by Natalie Aster
New research study “Infectives Partnering Terms and Agreements” by CurrentPartnering provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies. It covers the following information:
- Trends in infectives partnering deals
- Average deal terms for headline, upfront and royalty by stage of development
- Infectives partnering agreement structure
- Infectives partnering contract documents
- Top infectives deals by value
- Most active infectives dealmakers
The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 2,000 links to online copies of actual infectives deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Infectives Partnering Terms and Agreements
Published: July, 2012
Price: US$ 1.995,00
The initial chapters of this report provide an orientation of infectives dealmaking and business activities. Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in infectives dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.
Chapter 3 provides a review of the leading infectives deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of infectives deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides comprehensive access to all infectives deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all infectives partnering deals signed and announced since 2007. The chapter is organized by specific infectives therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all infectives partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in infectives partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of infectives technologies and products.
More information can be found in the report “Infectives Partnering Terms and Agreements” by CurrentParnering.
To order the report or ask for sample pages contact [email protected]